News Search Results
Oct 30, 2025, 16:54 ET BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in
More news about: BioVaxys Technology Corp.
Oct 30, 2025, 07:35 ET Knight Therapeutics anuncia la aprobación y el lanzamiento de MINJUVI® (tafasitamab) en Argentina
combinación con lenalidomida para el tratamiento de pacientes adultos con linfoma difuso de células B grandes (DLBCL) recidivante o refractario no especificado de otra manera, incluido el DLBCL derivado de linfoma de bajo grado, y que no son candidatos para TACM. En Europa, MINJUVI® (tafasitamab) recibió
More news about: Knight Therapeutics Inc.
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
scheme. It is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma (DLBCL) in both second- and third-line settings, with additional studies evaluating its potential in first-line DLBCL, B-cell neoplasms, and mantle cell lymphoma (MCL).
More news about: DelveInsight Business Research, LLP
Oct 28, 2025, 07:00 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in
More news about: BioVaxys Technology Corp.
Oct 27, 2025, 07:00 ET Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Oct 22, 2025, 03:45 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in
More news about: BioVaxys Technology Corp.
Oct 20, 2025, 19:39 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in
More news about: BioVaxys Technology Corp.
Oct 14, 2025, 08:00 ET BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in
More news about: BioVaxys Technology Corp.
Oct 13, 2025, 07:30 ET ADC Therapeutics Announces $60 Million Private Placement
relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated
More news about: ADC Therapeutics SA
Oct 08, 2025, 08:00 ET BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS
maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in
More news about: BioVaxys Technology Corp.
Oct 08, 2025, 07:00 ET Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Oct 07, 2025, 17:30 ET BIOVAXYS ANNOUNCES LIFE OFFERING
maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in
More news about: BioVaxys Technology Corp.
Oct 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.